“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Opinion|Videos|December 23, 2024
Assessing Patient Eligibility for CAR-T Therapy
This segment explores factors influencing patient candidacy for CAR-T therapy, including age, fitness, and relapse specifics, and evaluates key findings from the KarMMa trials to compare ide-cel with other second-line treatment options for multiple myeloma.
Advertisement
Video content above is prompted by the following:
- What factors make Rosie a strong candidate for CAR-T therapy?
- How do considerations like her age, overall fitness, and specifics of her relapse shape your decision?
- Are there other treatment paths you would explore for this patient?
- Let’s examine the data backing the use of ide-cel in this context:
- Which major findings from the KarMMa and KarMMa-3 trials are most relevant to your decision-making?
- How do these outcomes compare with other second-line options available for multiple myeloma?
Advertisement
Related to this article
Data from the phase 3 CERVINO trial support the application for etentamig as a treatment for adults with relapsed or refractory multiple myeloma.
The MagnetisMM-32 trial may support elranatamab as an important option for those whose disease has progressed following anti-CD38 therapy and lenalidomide.
Advertisement
Advertisement
Trending on CancerNetwork
1
AI-Measured Tumor Volume on PSMA PET-CT Linked With Survival in Prostate Cancer
2
How Could Rocbrutinib Plus R-CHOP Reshape Frontline Non-GCB DLBCL Treatment?
3
Expanding Access to Advanced Radiation Services Across a Network
4
Sac-TMT Earns FDA Priority Review in Pretreated Endometrial Cancer
5